Published in Ann Rheum Dis on September 19, 2006
The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther (2010) 1.26
Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides. Arthritis Res Ther (2012) 1.13
A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis (2011) 1.05
Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum (2008) 1.05
Anti-CCP2 antibodies: an overview and perspective of the diagnostic abilities of this serological marker for early rheumatoid arthritis. Clin Rev Allergy Immunol (2008) 1.03
Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis. Rheumatol Int (2008) 1.03
The anti-cyclic citrullinated peptide response in tuberculosis patients is not citrulline-dependent and sensitive to treatment. Arthritis Res Ther (2010) 1.00
Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis. Rheumatol Int (2010) 0.87
Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol (2009) 0.87
The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. Rheumatol Int (2009) 0.83
IgG RF and anti-CCP2 antibody can be positive in undifferentiated arthritis due to streptococcal infection, hepatitis B virus, tuberculosis, trauma and hypothyroidism: a preliminary study. Rheumatol Int (2011) 0.79
Diagnostic utility of anti-cyclic citrullinated peptide antibodies for rheumatoid arthritis in patients with active lung tuberculosis. Clin Rheumatol (2008) 0.76
Meta-Analysis: Diagnostic Accuracy of Anti-Carbamylated Protein Antibody for Rheumatoid Arthritis. PLoS One (2016) 0.75
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum (2003) 10.65
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest (1998) 6.92
PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays (2003) 5.04
Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis (2003) 2.53
Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med (2002) 2.53
Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem (2001) 2.01
Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol (2004) 1.57
Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis (2004) 1.35
Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (2001) 1.34
Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis (2005) 1.31
Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev (2006) 1.16
Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology (Oxford) (2003) 1.11
Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis (2005) 1.06
Absence of citrulline-specific autoantibodies in animal models of autoimmunity. Arthritis Rheum (2004) 1.00
Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol (2006) 0.98
Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis (2005) 0.97
Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther (2005) 0.94
Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance. J Gastroenterol (2002) 0.94
Autoantibodies to citrullinated (poly)peptides: a key diagnostic and prognostic marker for rheumatoid arthritis. Autoimmunity (2004) 0.91
Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol (2001) 0.91
Type 1 autoimmune hepatitis revealed by a dysphonia related to cricoarytenoid arthritis. QJM (2003) 0.90
Treatment strategies in autoimmune hepatitis. Clin Liver Dis (2002) 0.86
Autoimmune tests in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol (2000) 0.86
Anti-cyclic citrullinated peptide autoantibodies in IgM rheumatoid factor-positive patients. Clin Chim Acta (2005) 0.85
[Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: relation with clinical features, cytokines and HLA-DRB1]. Biomedica (2004) 0.85
Autoimmune hepatitis. Making sense of all those antibodies. Postgrad Med (2003) 0.83
[Primary and secondary autoimmunity in hepatology]. Ann Ital Med Int (2000) 0.78
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Global patterns of linkage disequilibrium at the CD4 locus and modern human origins. Science (1996) 8.25
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest (1998) 6.92
Identification of the RNA binding segment of human U1 A protein and definition of its binding site on U1 snRNA. EMBO J (1989) 4.69
Major determinants of the specificity of interaction between small nuclear ribonucleoproteins U1A and U2B'' and their cognate RNAs. Nature (1990) 4.67
Polymyositis: an overdiagnosed entity. Neurology (2003) 4.36
The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2000) 4.10
cDNA cloning of the human U1 snRNA-associated A protein: extensive homology between U1 and U2 snRNP-specific proteins. EMBO J (1987) 3.47
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum (2004) 3.38
hnRNA and its attachment to a nuclear protein matrix. J Cell Biol (1981) 2.88
Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis (2004) 2.82
Analysis of a cDNA clone expressing a human autoimmune antigen: full-length sequence of the U2 small nuclear RNA-associated B" antigen. Proc Natl Acad Sci U S A (1987) 2.75
The human U1 snRNP-specific U1A protein inhibits polyadenylation of its own pre-mRNA. Cell (1993) 2.58
Aberrant expression of HLA-DR antigens on bileduct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet (1984) 2.38
Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis (2008) 2.27
Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis (2006) 2.24
Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology (1997) 2.21
The U2B'' RNP motif as a site of protein-protein interaction. EMBO J (1990) 2.12
Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum (2007) 2.10
Cross-linking of mRNA to proteins by irradiation of intact cells with ultraviolet light. Eur J Biochem (1980) 2.04
Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther (2005) 2.03
Human U1 snRNP-specific C protein: complete cDNA and protein sequence and identification of a multigene family in mammals. Nucleic Acids Res (1988) 2.02
Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor? Arthritis Rheum (2011) 2.01
The association of the U1-specific 70K and C proteins with U1 snRNPs is mediated in part by common U snRNP proteins. EMBO J (1994) 2.00
Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem (1998) 1.97
Monospecific antibodies reveal details of U2 snRNP structure and interaction between U1 and U2 snRNPs. EMBO J (1986) 1.96
Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease. Clin Exp Immunol (1983) 1.92
Neuroimaging, physical, and developmental findings after inflicted and noninflicted traumatic brain injury in young children. Pediatrics (1998) 1.89
hPop1: an autoantigenic protein subunit shared by the human RNase P and RNase MRP ribonucleoproteins. EMBO J (1996) 1.87
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Characterization of the SS-B (La) antigen in adenovirus-infected and uninfected HeLa cells. EMBO J (1983) 1.83
Value of molecular analysis of Wilson's disease in the absence of tissue copper deposits: a novel ATP7B mutation in an adult patient. Neth J Med (2008) 1.77
Analysis of protein--RNA interactions within Ro ribonucleoprotein complexes. Nucleic Acids Res (1991) 1.76
Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. J Mol Biol (1999) 1.75
Nav1.7-related small fiber neuropathy: impaired slow-inactivation and DRG neuron hyperexcitability. Neurology (2012) 1.73
Intrauterine surgery under intravenous sedation as an outpatient alternative to hysterectomy. Lancet (1989) 1.73
Three novel components of the human exosome. J Biol Chem (2000) 1.72
NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci (2008) 1.70
Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis (1991) 1.68
Factors influencing the career choices of general practitioner trainees in North West Thames Regional Health Authority. Br J Gen Pract (1993) 1.65
In vitro reconstitution of mammalian U1 snRNPs active in splicing: the U1-C protein enhances the formation of early (E) spliceosomal complexes. Nucleic Acids Res (1996) 1.62
Quantitation of anti-RNP and anti-Sm antibodies in MCTD and SLE patients by immunoblotting. Clin Exp Immunol (1985) 1.62
A complex secondary structure in U1A pre-mRNA that binds two molecules of U1A protein is required for regulation of polyadenylation. EMBO J (1993) 1.62
The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol (2000) 1.61
Adenoviral heterogeneous nuclear RNA is associated with the host nuclear matrix during splicing. J Mol Biol (1982) 1.60
U1 small nuclear ribonucleoprotein particle-specific proteins interact with the first and second stem-loops of U1 RNA, with the A protein binding directly to the RNA independently of the 70K and Sm proteins. Mol Cell Biol (1989) 1.56
Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63. Clin Genet (2010) 1.55
Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis (2006) 1.54
Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut (2000) 1.53
Internet-based support for bioscience research: a collaborative genome center for human chromosome 12. J Am Med Inform Assoc (1996) 1.50
Characterization of the microsomal antigen related to a subclass of active chronic hepatitis. Immunology (1974) 1.50
Evaluating the child for sexual abuse. Am Fam Physician (2001) 1.49
Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med (2005) 1.48
Prevalence of silent coeliac disease in atopics. Dig Liver Dis (2000) 1.48
On the association of mRNA with the cytoskeleton in uninfected and adenovirus-infected human KB cells. Exp Cell Res (1981) 1.48
Genetic factors associated with naevus count and dermoscopic patterns: preliminary results from the Study of Nevi in Children (SONIC). Br J Dermatol (2015) 1.47
Desmin and actin in the identification of Ito cells and in monitoring their evolution to myofibroblasts in experimental liver fibrosis. Virchows Arch B Cell Pathol Incl Mol Pathol (1988) 1.47
Abdominal lymphadenopathy detected by ultrasonography in HIV-1 infection: prevalence and significance. Scand J Infect Dis (1993) 1.44
Anti tissue transglutaminase antibodies as predictors of silent coeliac disease in patients with hypertransaminasaemia of unknown origin. Dig Liver Dis (2001) 1.44
Scl-86, a marker antigen for diffuse scleroderma. J Clin Invest (1985) 1.43
The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther (2011) 1.42
Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum (2001) 1.42
Specificity in the interaction of hnRNA and mRNA with proteins as revealed by in vivo cross linking. FEBS Lett (1981) 1.42
RNA-protein interactions in the human RNase MRP ribonucleoprotein complex. RNA (1999) 1.41
Conserved amino acid residues within and outside of the N-terminal ribonucleoprotein motif of U1A small nuclear ribonucleoprotein involved in U1 RNA binding. J Mol Biol (1991) 1.40
IgA antibodies to endomysium, gliadin, and reticulin in silent coeliac disease. Lancet (1992) 1.40
Bile duct cell apoptosis is a rare event in primary biliary cirrhosis. Dig Liver Dis (2001) 1.40
Independent deposition of heterogeneous nuclear ribonucleoproteins and small nuclear ribonucleoprotein particles at sites of transcription. Proc Natl Acad Sci U S A (1992) 1.40
Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet (1991) 1.38
Thyroid function in systemic sclerosis. J Endocrinol Invest (1991) 1.38
[The anti-synthetase syndrome: muscle disease and multisystem disorder at the same time]. Ned Tijdschr Geneeskd (2003) 1.38
Vogt-Koyanagi-Harada syndrome. Autoimmun Rev (2013) 1.35
High prevalence of celiac disease in Italian general population. Dig Dis Sci (2001) 1.34
Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci (1998) 1.34
Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxford) (2005) 1.34
Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (2001) 1.34
Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet (1998) 1.33
Ro ribonucleoprotein assembly in vitro. Identification of RNA-protein and protein-protein interactions. J Mol Biol (1992) 1.31
Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet (1990) 1.30
Injuries in youth amateur soccer and rugby players--comparison of incidence and characteristics. Br J Sports Med (2004) 1.30
The ribosome cycle in mammalian protein synthesis. II. Association of the native smaller ribosomal subunit with protein factors. J Biol Chem (1973) 1.30
Somatic insertions and deletions shape the human antibody repertoire. J Mol Biol (1999) 1.28
Antibodies to gliadin detected by immunofluorescence and a micro-ELISA method: markers of active childhood and adult coeliac disease. Gut (1985) 1.28
Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther (2012) 1.27
Architecture and function of the human endonucleases RNase P and RNase MRP. IUBMB Life (2000) 1.25
Somatostatin analogues reduce liver volume in polycystic liver disease. Gut (2008) 1.25
Subcellular distribution of Ro ribonucleoprotein complexes and their constituents. J Cell Sci (1993) 1.24
Immunomorphological characterisation of antinuclear antibodies in chronic liver disease. J Clin Pathol (1985) 1.23
HCV and autoimmunity. Curr Pharm Des (2008) 1.22
Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis (2006) 1.22
Zinc finger-like structure in U1-specific protein C is essential for specific binding to U1 snRNP. Nucleic Acids Res (1991) 1.22
The interactions with Ro60 and La differentially affect nuclear export of hY1 RNA. RNA (1996) 1.21